{"name":"Coalition for National Trauma Research","slug":"coalition-for-national-trauma-research","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pathogen-Reduced Plasma","genericName":"Pathogen-Reduced Plasma","slug":"pathogen-reduced-plasma","indication":"Coagulation factor replacement in patients requiring plasma transfusion","status":"marketed"}]}],"pipeline":[{"name":"Pathogen-Reduced Plasma","genericName":"Pathogen-Reduced Plasma","slug":"pathogen-reduced-plasma","phase":"marketed","mechanism":"Pathogen-reduced plasma is human blood plasma treated with a pathogen reduction technology to inactivate or remove infectious agents while preserving hemostatic function.","indications":["Coagulation factor replacement in patients requiring plasma transfusion","Volume expansion and hemostatic support in acute bleeding or surgical settings"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}